Following the contamination of blood products with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in the 1970s to 1980s, almost all hemophilia patients who received plasma-derived factor products were infected with HCV prior to the implementation of viral inactivation in 1985. Of these patients, around 20% spontaneously cleared the virus [1,2]. The remainder developed chronic hepatitis and around 30% of them cirrhosis and finally hepatocellular carcinoma (HCC) in the absence of treatment [2,3].
